Synonyms: compound 31 [PMID: 30247908] | TUG1375
Compound class:
Synthetic organic
Comment: TUG-1375 was designed as a selective free fatty acid receptor 2 (FFA2/GPR43) agonist, as a pharmacological tool that is suitable for the study of FFA2 receptor function in vitro and in vivo [1]. FFA2 is known to be involved in regulation of metabolism, appetite, fat accumulation and inflammatory responses.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Hansen AH, Sergeev E, Bolognini D, Sprenger RR, Ekberg JH, Ejsing CS, McKenzie CJ, Rexen Ulven E, Milligan G, Ulven T. (2018)
Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. J Med Chem, 61 (21): 9534-9550. [PMID:30247908] |
2. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J et al.. (2003)
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem, 278 (28): 25481-9. [PMID:12711604] |
3. Ulven T. (2012)
Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne), 3: 111. [PMID:23060857] |